PI3K/mTOR-IN-22

PI3K/mTOR-IN-22 (Compound J-33) is a selective dual inhibitor of PI3K and mTOR kinases, with an IC₅₀ of 400.5 nM for PI3Kα and 8.2 nM for mTOR, and forms stable binding interactions with both kinases^[1].
PI3K/mTOR-IN-22 potently inhibits proliferation of MCF-7 human breast cancer cells with an IC₅₀ of 1.5 μM, and also inhibits proliferation of H1975, H460, PC-9 cells with IC₅₀ values of 10.7, 2.3 and 13.5 μM^[1].
PI3K/mTOR-IN-22 (256 μg/mL) exhibits low hemolytic toxicity in sheep erythrocytes, with a hemolysis rate of 2.60%^[1].
PI3K/mTOR-IN-22 (0.75-1.50 μM; 6-12 h) induces concentration-dependent apoptosis in MCF-7 human breast cancer cells, reduces mitochondrial membrane potential and increases intracellular ROS levels^[1].
PI3K/mTOR-IN-22 (0.75-1.50 μM; 24 h) dose-dependently inhibits migration of MCF-7 human breast cancer cells in vitro, as shown by the wound healing assay^[1].
PI3K/mTOR-IN-22 (0.19-3.00 μM; 14 days) dose-dependently inhibits clonogenicity of MCF-7 human breast cancer cells^[1].
PI3K/mTOR-IN-22 (0.75-6.00 μM) dose-dependently downregulates phosphorylation of AKT and mTOR in MCF-7 human breast cancer cells, inhibiting the PI3K-AKT-mTOR signaling pathway^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.